Vulvodynia Treatment Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Vulvodynia Treatment Market Analysis

The vulvodynia treatment market is expected to register a CAGR of nearly 9% over the forecast period.

The COVID-19 pandemic significantly impacted the vulvodynia treatment market. As per an article published in February 2022 by Elsevier Public Health Emergency Collection, the COVID-19 pandemic posed significant obstacles to clinical practice, delaying the management of patients with curable conditions, including urogynecological conditions. Such studies indicate that the number of visits for vulvodynia treatment was reduced during the pandemic, thereby depicting a short-term negative impact on the market. However, with the introduction of vaccines and the upliftment of lockdown restrictions, the market is expected to show healthy growth in the coming period.

The market's growth is attributed to the factors such as increasing prevalence pertaining to vulvodynia and new emerging treatments for vulvodynia. For instance, as per an article in June 2021 published by Frontiers Media SA, the prevalence of localized provoked vulvodynia varies between 8-18% in the population. Localized provoked vulvodynia is a poorly recognized condition. 50% of symptomatic women sought care, 30% had three or more physician visits, and 40% remained undiagnosed. Additionally, according to an article published by Sexual Medicine in August 2021, itraconazole therapy is associated with a significant reduction in vulvovaginal pain in patients with negative fungus cultures. Also, according to an article published by National Vestibulodynia Association, in August 2022, Meclon Lenex vulvar emulgel revealed excellent tolerability and compliance, demonstrating to be a safe and effective option in the treatment of provoked vestibulodynia. Thus, new emerging treatments for vulvodynia are expected to drive the growth of the market over the forecast period.

The companies are actively involved in new product launches and approval, developments, and collaborations to expand their footprint. For instance, in April 2022, the US Food and Drug Administration (FDA) approved Mycovia Pharmaceuticals' VIVJOATM (oteseconazole), the first and only treatment for recurrent vaginal candidiasis. Such developments are expected to drive the growth of the market over the forecast period.

The above-mentioned factors are expected to drive the market's growth across the world. However, low awareness pertaining to vulvodynia and the lack of approved products are the major factors hindering the market's growth.

Vulvodynia Treatment Market Trends

This section covers the major market trends shaping the Vulvodynia Treatment Market according to our research experts:

Local Anesthetics Segment Expected to Hold a Significant Share in the Vulvodynia Treatment Market

Vulvodynia Treatment Industry Segmentation

As per the scope of this report, vulvodynia, or pain in the vulva, is a chronic condition characterized by burning, stinging, and stabbing sensations. The treatment for vulvodynia includes avoiding irritants such as tight-fitting clothing, perfumes, and dyes, as well as medications such as local anesthetic and nerve medication, among other medications. The Vulvodynia Treatment Market is Segmented by Drug Type (Local Anesthetics, Anticonvulsants, Tricyclic Antidepressants, Antimicrobials, and Other Drug Types), Mode of Administration (Oral, Topical, and Injectable), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above-mentioned segments.